|
|
|
|
|
10.06.25 - 19:33
|
Agenus Announces Virtual Annual Shareholders Meeting (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.
To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.
Webcast Information:
Date: Tuesday, June 17, 2025
Time: 10:30 a.m. ET
A live webcast and replay will be accessible on the Company's website at https://investor.agenusbio.com/events-and-presentations and at www.virtualshareholdermeeting.com/AGEN2025.
Voting Information:
Shareholders of Agenus as of the April 24th, 2025, record date can vote. Alliance Advisors, Agenus's proxy solicit...
|
|
|
|
|
04.06.25 - 03:54
|
Agenus und Zydus Lifesciences gehen strategische Zusammenarbeit im Wert von 141 Millionen US-Dollar ein, um BOT/BAL voranzutreiben und die Biologika-Produktion von Zydus in den USA auszuweiten (Business Wire)
|
|
|
75 Mio. US-Dollar Vorauszahlung an Agenus für die Übertragung von Produktionsanlagen
50 Mio. US-Dollar bedingte Zahlungen an Agenus
Exklusive Lizenz für BOT/BAL in Indien und Sri Lanka
16 Mio. US-Dollar Kapitalbeteiligung zu 7,50 US-Dollar pro Aktie
LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. ( Nasdaq: AGEN), ein führendes Unternehmen im Bereich der immunonkologischen Innovation, gab heute bekannt, dass es endgültige Partnerschaftsvereinbarungen mit Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), einschließlich ihrer Tochtergesellschaften/verbundenen Unternehmen, im Folgenden als „Zydus“ bezeichnet, um die klinische Entwicklung zu beschleunigen, die weltweite Produktion auszuweiten und den Zugang von Patienten zu Botensilimab und Balstilimab (BOT/BAL) zu verbessern.
Die strategische Zusammenarbeit umfasst den Austausch der hochmodernen CMC-Einrichtungen für Biologika von Agenus in Emeryville, Kalifornien, und Berkeley, Kalifornien, gegen eine Vorabzahlung in Höhe von 75 Millionen US-Doll...
|
|
|
|
|
|
|
03.06.25 - 13:55
|
XFRA: AJ8: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
AGENUS INC. DL-,01 AJ8 US00847G8042
AB/FROM ONWARDS 03.06.2025 13:48 CET...
|
|
|
03.06.25 - 13:25
|
XFRA: AJ8: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
AGENUS INC. DL-,01 AJ8 US00847G8042 BAW/UFN...
|
|
|
|
|
03.06.25 - 13:03
|
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus′ Biologics Manufacturing in the US (Business Wire)
|
|
|
$75M upfront payment to Agenus for the transfer of manufacturing assets
$50M of contingent payments to Agenus
Exclusive license for BOT/BAL in India and Sri Lanka
$16M equity investment at $7.50 per share
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL).
The strategic collaboration includes an exchange of Agenus' state-of-the-art biologics CMC facilities in Emeryville, CA and Berkeley, CA for upfront consideration of $75M; Agenus to receive up to an additional $50M in contingent payments triggered by BOT/BAL production orders. Zydus, an India-based multinational pharmaceutical company with over 27,000 employees and operations in...
|
|
|
30.05.25 - 13:33
|
Agenus Presents New Data at ASCO Highlighting Botensilimab′s Immune Activation in MSS Colorectal Cancer (Business Wire)
|
|
|
Study shows botensilimab “switches on” the body's own T-cells to attack a common, treatment-resistant form of colorectal cancerLEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic colorectal cancer (mCRC)—a tumor type traditionally resistant to immunotherapy and representing approximately 85-95% of all colorectal cancers. T cells are key immune cells capable of recognizing and attacking cancer cells. Activating these typically 'cold' tumors and driving a strong T cell response suggests that botensilimab has the potential to overcome resistance and improve patient outcomes.
The research was led by Dr. Gertjan Rasschaert of Leuven University Hospitals in collabor...
|
|
|
|
|
|
|
|
|
12.05.25 - 13:36
|
Agenus Reports Q1 2025 Financial Results and Key Business Updates (Business Wire)
|
|
|
BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success
Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration Milestones
Near-Term Capital Transaction Poised to Bolster Liquidity
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program.
“The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinforces our conviction in its transformative potential and fuels our unwavering commitment to delivering this combination to patients,” said Garo Armen, Ph.D., Chairman and CEO of Agenus. “With expanded datasets, key leadership appointments, and the FDA's renewed focus on accelerating cures and meaningful treatments, Agenus is enteri...
|
|
|
12.05.25 - 13:24
|
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointestinal (GI) cancer treatment and research, has joined the company as Chief Development Officer. In this role, Dr. Goldberg will lead efforts to advance the botensilimab/balstilimab (BOT/BAL) program for patients and guide the company's regulatory and development strategy as it prepares to re-engage global health authorities.
Dr. Goldberg's distinguished career spans over four decades, during which he has made significant contributions to oncology through clinical practice, research, and leadership.
“Five years ago, I stepped away from formal cancer center leadership roles in academic oncology and from clinical practice. That afforded me time to apply my skills differently by advising companies developing new drugs and technologies for treating GI cancers and particularly colorectal cancer. I also used th...
|
|
|
|
|
29.04.25 - 13:33
|
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Conference Call:
To access dial-in numbers, please register here.
Conference ID: 73242
A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/903911751.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of a...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
